Tagged with ART

Denmark Lisbeth Nielsen of the Danish Health Data Authority outlines the organisation’s purpose and mission, how it contributed to Denmark’s robust COVID-19 response, and the challenges of making Denmark’s comprehensive patient data sets available to researchers while maintaining patient confidentiality and trust.   One of the Health Data Authority’s most important…

Global Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape today and how Novartis interacts with it, the work being done on patient engagement and expectation management for the firm’s cutting-edge CAR-T therapies, and how a stronger patient voice can…

InFocus HOMEPAGE Patient Engagement in the Era of CAR-T In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand…

Global After 20 years, Novartis will no longer own one third of Roche’s shares after the two Swiss pharma giants agreed to a transaction worth USD 20.7 billion. While Roche touted the deal as the regaining of “full strategic flexibility”, Novartis argued that it was the right time to “monetize” its…

Singapore Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in Europe and the US – needs to be developed, and how Novartis has been working with patients in the region around its CAR-T therapies.   It…

Denmark Data has been collected within Danish healthcare for more than 40 years, extending beyond the national patient registry to include a broad range of data points, from IVF to the birth registry, abortion, the weight and height of children, and much more. Danes tend to have a high level of…

Turkey In the world’s 18th largest market, recent pricing struggles have pushed some companies to revaluate their investment approach. Multinational organizations are complying with localization policies but are divided between having their own plant or partnering with a local CMO provider – although all of them appear to agree on one…

Denmark Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the strategy in place to navigate an increasingly challenging market access landscape, and the lessons that can be leveraged from the value-based agreement that Novartis was able to strike with the…

Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…

Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…

APAC The Asia-Pacific (APAC) region is home to around 1.44 billion people, over 60 percent of the world’s population, and a vast diversity of cultures, infrastructures, and economic development. Managing a life sciences company across multiple countries in this region can be extremely challenging but hugely important on both a human…

China The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in the first half of the year despite pricing squeezes on their mature brands; and why Bayer sees huge growth potential…